Lynch syndrome represents one of the most prevalent hereditary cancer syndromes identified to date, yet awareness remains alarmingly sparse. Dr. Bryson Katona, MD, PhD, co-founder and inaugural executive director of the King Center, emphasizes this gap in public consciousness: “Despite Lynch syndrome’s high incidence as a genetic cause of cancer, many affected individuals and healthcare providers remain unaware of its existence or implications.” The substantial donation from the King and Borrelli families aims to transform this landscape by expanding cutting-edge research endeavors, lifetime patient care strategies, and public education.

The genesis of this generous philanthropy is deeply personal. The King and Borrelli families have been long-standing proponents of Lynch syndrome research, motivated by intimate battles with the condition. The late Jeffery King’s diagnosis in his late sixties, following a second Lynch-related cancer, underscores the critical need for early detection and awareness. His daughter, Julie Borrelli, contrasts her experience, having accessed genetic testing and personalized cancer risk management at a much earlier age, demonstrating the tangible benefits of proactive intervention.

At a molecular level, Lynch syndrome arises from germline mutations in critical DNA mismatch repair (MMR) genes—MLH1, MSH2, MSH6, PMS2, and EPCAM. These genes function as guardians of genomic integrity by correcting replication errors that, if unchecked, predispose cells to malignant transformation. Dysfunctional MMR due to hereditary mutations compromises this surveillance system, precipitating microsatellite instability and an increased mutational burden that propels oncogenesis across various tissues.

The clinical consequences of Lynch syndrome are profound. While the general population faces about a 4% lifetime risk of colorectal cancer and approximately 3% for uterine cancer, individuals with Lynch syndrome can see these risks soar dramatically—ranging from 9% to 60% for colorectal cancer, and between 13% to nearly 60% for endometrial cancer, depending on their specific mutational profile. Additional malignancies such as gastric, urinary tract, pancreatic, ovarian, and certain skin cancers also occur with elevated likelihood, though to a lesser degree.

Managing this heightened risk requires a comprehensive, personalized paradigm. Lynch syndrome carriers necessitate intensified surveillance regimens that commence earlier and occur more frequently than standard population guidelines. The multifaceted nature of associated cancer risks demands an expert coordinator—typically a Lynch syndrome specialist—to orchestrate and tailor screenings across organ systems. This ensures no aspect of the hereditary risk spectrum is overlooked, fostering timely detection and prevention.

However, clinical management challenges persist. According to Jessica Long, MS, CGC, director of education and outreach for the King Center, many patients undergo colonoscopies without comprehensive counseling on their uterine cancer risk or proactive familial risk assessment. This fragmented care underscores the importance of centralized expertise capable of delivering holistic, evidence-based surveillance and facilitating genetic counseling for affected families.

Beyond clinical care, Lynch syndrome research is rapidly evolving. The King Center supports a robust research portfolio spanning basic science, translational studies, and clinical trials, empowered by philanthropic funding. Remarkably, over 1,200 blood samples and extensive biopsy and stool collection cohorts enrich the Lynch Syndrome Immune Profiling Project at Penn, enabling scientists to interrogate immune mechanisms that modulate individual cancer risk variability.

Dr. E. John Wherry, PhD, co-founder of the King Center and chair of the Department of Systems Pharmacology and Translational Therapeutics, highlights the intriguing heterogeneity in cancer risk manifestation among Lynch syndrome carriers. His research explores the interplay between tumor immunology and genetic susceptibility, aspiring to refine personalized risk predictions and devise tailored immunotherapeutic strategies that preempt cancer development in these high-risk populations.

Currently, close to 1,000 patients receiving care at Penn Medicine for Lynch syndrome—many of whom traverse significant distances within the Northeast to access expert services—benefit from multidisciplinary approaches that integrate leading-edge genomics, immunology, and oncology. The King Center will amplify these efforts by expanding education initiatives for patients, families, and healthcare professionals, and by accelerating clinical trial enrollment targeting novel therapies and early detection methodologies.

In addition to patient-centered advancements, the King Center endeavors to fortify public health outreach by raising Lynch syndrome awareness, thereby bridging the knowledge deficit that impedes widespread genetic testing and surveillance adoption. Events such as the upcoming 5th Annual Lynch Syndrome Symposium serve as vital platforms for disseminating the latest research findings, clinical guidelines, and innovations in risk management.

The establishment of the King Center for Lynch Syndrome represents a transformative milestone, poised to catalyze significant progress in understanding and combating hereditary cancer risk. By marrying philanthropic vision with scientific rigor and compassionate care, Penn Medicine reaffirms its commitment to revolutionizing oncology and empowering individuals with Lynch syndrome to live longer, healthier lives.

Subject of Research: Lynch syndrome hereditary cancer research and patient care innovation

Article Title: Penn Medicine Launches World’s First Named Center for Lynch Syndrome with $10 Million Philanthropic Gift

News Publication Date: March 2026

Web References:
– King Center for Lynch Syndrome: https://www.med.upenn.edu/kingcenter/
– Lynch Syndrome Information: https://www.pennmedicine.org/conditions/lynch-syndrome
– Abramson Cancer Center: https://www.pennmedicine.org/specialties/cancer/about-abramson-cancer-center

Keywords: Lynch syndrome, hereditary cancer, DNA mismatch repair, colorectal cancer, endometrial cancer, cancer genetics, personalized cancer risk management, genetic counseling, cancer screening, immunology, translational research, Penn Medicine, Abramson Cancer Center

Among the foremost scientific highlights is the work of Dr. M. Celeste Simon, Arthur H. Rubenstein Professor in Cell and Developmental Biology, who will explore the intriguing potential of targeting metabolic pathways as a modality for curing liver and other malignancies. Her talk, scheduled for April 26 in the Discovery Science Plenary session, underscores the growing appreciation of cancer cell metabolism—not simply as a consequence of tumorigenesis but as an active driver and therapeutic vulnerability. Simon’s research delves into how altered metabolic fluxes create metabolic dependencies that can be exploited to selectively eradicate tumor cells without harming normal tissue.

Complementing this metabolic focus, Dr. Shelley L. Berger—a distinguished molecular biologist and recipient of the AACR-Women in Cancer Research Charlotte Friend Lectureship—will deliver a keynote addressing epigenetic regulation and its profound implications for cancer progression and therapy. Dr. Berger’s investigations explore how dynamic chromatin states influence gene expression programs that fuel malignancy. Her pioneering work reveals how epigenetic modulators can be targeted to reverse aberrant transcriptional patterns, thereby restoring cellular controls lost during cancer evolution.

Equally compelling are presentations by Penn’s emerging scientific talents, particularly those centered on the intersection of metabolism and epigenetics in treatment-resistant cancers. Dr. Christina Demetriadou, from Dr. Kathryn E. Wellen’s laboratory, will report findings that elucidate how branched-chain amino acid metabolism contributes to histone propionylation in pancreatic cancer cells. This novel epigenetic modification links nutrient metabolism directly to chromatin remodeling, influencing tumor cell proliferation and survival. Unraveling this metabolic-epigenetic crosstalk offers a promising avenue to disrupt aggressive pancreatic ductal adenocarcinoma, a cancer notoriously refractory to conventional therapies.

In the realm of targeted therapeutics, graduate student Gianna T. Busch will present studies exploring the heterogeneous responses of therapy-resistant melanoma cells to second-line inhibitors. Melanomas harboring the BRAFV600E mutation frequently develop resistance to frontline BRAF inhibitors, prompting the need for innovative combination strategies to circumvent relapse. Busch’s work utilizes high-resolution genetic and phenotypic analysis to identify drug combinations that surmount resistance mechanisms, thereby improving durable responses against this formidable skin cancer.

Adding another dimension to cancer treatment, Margo I. Orlen will discuss breakthroughs in KRAS-targeted therapy in pancreatic cancer models, a domain long hampered by the ‘undruggable’ nature of RAS oncogenes. Orlen’s research, recently published in Cancer Discovery, demonstrates that RAS(ON) multi-selective inhibition not only impairs tumor growth but also reprograms the tumor microenvironment to enhance immune infiltration. By recruiting T cells and other immune effectors, this approach synergizes with immunotherapy, heralding a new paradigm for treating KRAS-driven malignancies.

Penn researchers are simultaneously advancing proteolysis-targeting chimera (PROTAC) technology to promote selective degradation of oncogenic proteins. Postdoctoral investigator Sehbanul Islam will reveal insights into the combinatorial application of VHL and KEAP1-based PROTACs, which show unanticipated synergy and mechanisms that alleviate the ‘hook effect’—a phenomenon that limits PROTAC efficacy at higher concentrations. These findings have fundamental implications for designing next-generation degraders with improved therapeutic windows and specificity.

Radiation oncology is also witnessing transformative innovation at Penn. Premed student Elias El Hoyek will present data demonstrating how FLASH proton radiotherapy—a technique delivering ultra-high dose rates of radiation—significantly reduces corneal damage and accelerates wound healing in murine models. These preclinical results herald a new era in radiotherapy that maximizes tumor eradication while minimizing damage to surrounding healthy tissue, a long-standing challenge in radiation oncology practice.

Bridging immunotherapy and nanotechnology, Dr. Khuloud Bajbouj’s research showcases the engineering of fibroblast activation protein (FAP)-directed CAR T cells via targeted lipid nanoparticles administered in situ. This novel delivery strategy enables robust, localized immune cell activation against the stromal components of pancreatic ductal adenocarcinoma, suppressing tumor progression. Such innovation exemplifies the increasing sophistication of tumor microenvironment-targeted therapies designed to overcome the immunosuppressive barriers erected by aggressive cancers.

In the genetics domain, postdoctoral researcher Mwangala Akamandisa will spotlight the tumor molecular landscape and therapeutic implications in young BRCA1/2 mutation carriers afflicted with breast cancer. These studies shed light on unique genomic profiles and vulnerabilities shaped by inherited mutations, informing tailored clinical management and precision oncology approaches for high-risk populations.

Together, these presentations reflect a broader thematic thrust at the AACR meeting to unravel the complexities of tumor biology through an integrated lens of metabolism, epigenetics, immunology, and therapeutic innovation. Penn Medicine’s contributions exemplify the power of multidisciplinary collaboration and cutting-edge biomedical research to generate transformative knowledge capable of driving next-generation cancer treatments.

The AACR Annual Meeting also provides a platform to honor distinguished leaders in the field. Dr. Shelley L. Berger’s recognition with the Charlotte Friend Lectureship highlights her seminal role in advancing cancer epigenetics and fostering women’s leadership in oncology. Additionally, the election of four Penn cancer researchers to the AACR Academy underscores the institution’s enduring prominence in the cancer research community.

As cancer continues to pose formidable challenges worldwide, the integration of novel scientific discoveries with translational strategies showcased by Penn Medical researchers offers hope for more effective, personalized, and less toxic therapies. The synergy between fundamental biology and clinical application present at this meeting exemplifies the trajectory toward curing cancers once deemed intractable.

In essence, the AACR 2025 Annual Meeting acts as a crucible for pioneering science, uniting researchers, clinicians, and trainees dedicated to decoding cancer’s complexity. The University of Pennsylvania’s robust representation affirms its commitment to transforming academic discoveries into clinical realities, thereby improving outcomes for patients confronting a spectrum of malignancies across the globe.

Subject of Research: Advances in cancer metabolism, epigenetics, immunotherapy, molecular oncology, and novel therapeutic approaches in diverse cancer types including pancreatic, melanoma, liver, and breast cancer.

Article Title: University of Pennsylvania Researchers Unveil Breakthroughs in Cancer Science at AACR Annual Meeting 2025

News Publication Date: April 2025

Web References:

• Abramson Cancer Center: https://www.pennmedicine.org/cancer
• Perelman School of Medicine: https://www.med.upenn.edu/
• AACR Annual Meeting 2025: https://www.aacr.org/meeting/aacr-annual-meeting-2025/
• Shelley Berger AACR Award: https://www.pennmedicine.org/news/news-releases/2025/april/shelley-berger-phd-honored-by-aacr-for-cancer-research
• M. Celeste Simon Profile: https://cdb.med.upenn.edu/people/m-celeste-simon-ph-d/

Keywords: Cancer research, metabolism, epigenetics, immunotherapy, KRAS inhibition, PROTACs, radiation therapy, CAR T cells, pancreatic cancer, melanoma, liver cancer, breast cancer, AACR 2025